BioNTech Acquires Biotheus to Boost Oncology Pipeline
Ticker: BNTX · Form: 6-K · Filed: Feb 3, 2025 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Feb 3, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, oncology, biotechnology
TL;DR
BioNTech just bought Biotheus to get more cancer drugs.
AI Summary
On February 3, 2025, BioNTech SE announced the successful acquisition of Biotheus, a clinical-stage biotechnology company focused on developing novel antibody-based therapies. This strategic move aims to expand BioNTech's oncology pipeline.
Why It Matters
This acquisition strengthens BioNTech's position in the oncology market by integrating Biotheus's promising antibody technologies, potentially leading to new cancer treatments.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a completed acquisition, with no immediate negative financial or operational implications disclosed.
Key Players & Entities
- BioNTech SE (company) — Acquiring company
- Biotheus (company) — Acquired company
- February 3, 2025 (date) — Date of acquisition announcement
FAQ
What type of company is Biotheus?
Biotheus is a clinical-stage biotechnology company dedicated to developing novel antibody-based therapies.
What is the primary focus of Biotheus?
Biotheus focuses on the discovery and development of antibody-based therapies, particularly in the field of oncology.
When did BioNTech SE announce the completion of the acquisition?
BioNTech SE announced the completion of the acquisition on February 3, 2025.
What is the strategic goal of BioNTech SE in acquiring Biotheus?
The strategic goal is to expand BioNTech's oncology pipeline by integrating Biotheus's technologies and assets.
What form is this SEC filing?
This SEC filing is a Form 6-K.
Filing Stats: 253 words · 1 min read · ~1 pages · Grade level 14.7 · Accepted 2025-02-03 07:02:25
Filing Documents
- form6-kbiotheusacquisition.htm (6-K) — 14KB
- a99_1250131xbntxpressstate.htm (EX-99.1) — 19KB
- image_0.jpg (GRAPHIC) — 102KB
- 0001776985-25-000004.txt ( ) — 174KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF FEBRUARY 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On February 3, 2025, BioNTech SE announced the completion of the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases. The press release is attached as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Jens Holstein By s Dr. Sierk Poetting Name Jens Holstein Name Dr. Sierk Poetting Title Chief Financial Officer Title Chief Operating Officer Date February 3, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech Completes Acquisition of Biotheus